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Abstract
Lambert–Eaton myasthenic syndrome (LEMS) is an autoimmune disease of
the neuromuscular junction and approximately 60% of LEMS patients have
a tumor, mostly small cell lung cancer, as a paraneoplastic neurological syn-
drome. LEMS patients develop a unique set of clinical characteristics, which
include proximal muscle weakness, depressed tendon reflexes with post-
tetanic potentiation and autonomic symptoms. Interestingly, slightly <10%
of LEMS patients have cerebellar ataxia (LEMS with paraneoplastic cerebellar
degeneration). Considering its pathomechanism, LEMS is a presynaptic dis-
order of neuromuscular transmission in which quantal release of acetyl-
choline is impaired by autoantibodies for P/Q-type voltage-gated calcium
channels at active zones, although an animal model by immunizing purified
P/Q-type voltage-gated calcium channels has not yet been successful.
Introduction
Lambert–Eaton myasthenic syndrome (LEMS) is a
rare presynaptic disorder of neuromuscular transmis-
sion in which quantal release of acetylcholine is
impaired by autoantibodies for voltage-gated calcium
channels, as shown in Figure 1.1–3 LEMS patients
develop a unique set of clinical characteristics, which
include proximal muscle weakness, depressed tendon
reflexes with post-tetanic potentiation and autonomic
changes.4 Interestingly, slightly <10% of LEMS
patients develop cerebellar ataxia, which was defined
as LEMS with paraneoplastic cerebellar degenera-
tion.5–10 Approximately 60% of LEMS patients have
an underlying malignancy, most commonly a small
cell lung cancer (SCLC); it is therefore regarded as a
paraneoplastic syndrome. In the present article, the
authors reviewed the clinical picture, pathology and
treatment of LEMS from a clinical point of view.
Epidemiology
The true incidence of LEMS in Japan is unknown. In
epidemiological studies (1990–1999) in the Nether-
lands, LEMS was 46-fold less prevalent (2.32 9 106)
than myasthenia gravis (MG; 106.1 9 106), whereas
the annual incidence rate of LEMS was 14-fold lower
(0.48 9 106) than that of MG (6.48 9 106).11 In
Table 1, three previous clinical studies of more than
50 patients with LEMS (O’Neill et al.,12 Nakao et al.13
and Titulaer et al.10) shared the following findings: (i)
it is male-dominated; (ii) the average age of onset is
50–60 years; and (iii) it is complicated by SCLC in
42–61% of patients. In 110 Japanese patients with
LEMS, the male-to-female ratio was 3:1, and the
average age of onset was 62 years within the 17–
80 years age range of patients. The incidence rate of
SCLC (paraneoplastic LEMS) in Japan is 61%, and
that of other cancers is 8%, and the remaining 31%
have non-paraneoplastic LEMS. Compared with other
reports, the epidemiological features of LEMS in
Japan show a low frequency of autonomic symptoms,
and the incidence rate of SCLC is high. Overall, LEMS
is a disease with common characteristic features
worldwide.
Symptoms, classification and prognosis
Nakao et al.13 reported in 2002 that more than 90% of
the initial neurological symptoms comprise a gait dis-
turbance as a result of the weakness of proximal leg
muscles, then awareness fatigability and a decrease in
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upper limb muscle strength. In severe cases, muscle
weakness of the body appears,14 including dysphagia,
as a result, leading to respiratory failure requiring arti-
ficial respiration.15,16 Other symptoms emerge as auto-
nomic neurological disorders, such as dry mouth,
mydriasis, blurred vision and bladder/rectal disorders,
in approximately 30% of patients.
The post-tetanic potentiation of deep tendon
reflexes is a specific neurological finding, in which
reduced deep tendon reflexes recover for a few sec-
onds after the maximal muscle contraction.
In addition, cerebellar ataxia occurs in <10% of
patients. Usually, the symptoms are not confined
only to the extraocular muscles, as in MG.17,18 In
LEMS patients, classification of severity, such as the
QMG score in MG, has not been reported.
The prognosis of LEMS patients varies greatly
depending on whether or not treatment is merged
with that for the malignant tumor, in particular of
SCLC.19,20 If SCLC is present at LEMS onset, and the
treatment for SCLC is responsive, the LEMS symp-
toms as well as the prognosis improve markedly.21
In contrast, if the treatment of SCLC does not go
well, life prognosis is limited to several years. In
2011, a joint study by the Netherlands and the UK
reported the DELTA-P score to predict the occur-
rence of SCLC at LEMS onset.22
Pathogenesis and pathology
The voltage-gated calcium channels (VGCC), which
are the target of the autoantibodies for LEMS, have
been classified as shown in Table 2. The VGCC of
Table 1 Comparison of the clinical pictures of Lambert–Eaton myas-










Male:female 32:18 84:26 55:42
Median age at onset (years) 54 62 57
Neurological findings (%)
Weakness of upper extremities 82 80 82
Weakness of lower extremities 90 97 100
Decreased deep tendon reflex 92 85 92
Ophthalmoplegia NA 5 38
Blepharoptosis 54 28 46
Sensory disturbance 4 10 NA
Cerebellar ataxia NA 9 9
Respiratory failure 6 5 NA
Autonomic symptoms (%)
Dry mouth 74 31 78
Constipation 18 11 29
Impaired sweating 4 7 NA
Impotence 26 4 65
Incidence of SCLC (%) 42 61 54
Seropositivity of P/Q-VGCC Ab (%) NA 85 93







Figure 1 (a) In the schematic diagram of normal neuromuscular junc-
tions (left), when the action potentials reach the nerve endings, Ca2+
flows from the outside of the cell to nerve endings inside. This influx is
carried out through the P/Q-type voltage-gated calcium channels pre-
sent at a high density in the active zone. When the Ca2+ concentration
in the nerve endings is raised, synaptic vesicles and membrane fuse
together. As a result, acetylcholine (ACh) is released from synaptic vesi-
cles, and binds to the acetylcholine receptor on the muscle side. (b) In
the electron microscope image shown, images of synaptic vesicles con-
taining ACh being released from the nerve terminals can be observed.
Agrin-MuSK-Lrp4 complexes are present in the dark high-electron den-
sity sites, which are the tip of the muscle side of the synapse folded
together with Ach receptor (AChR). Lrp4, low-density lipoprotein-recep-
tor related protein 4; M, mitochondria; MuSK, muscle-specific receptor
tyrosine kinase; NT, nerve terminal; preSM, presynaptic membrane; PSC,
primary presynaptic cleft; SSC, secondary presynaptic cleft; SV, synaptic
vesicle. Bar, 500 nm. Reproduced from Mitsuhiro61 with permission.
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nerve endings of the neuromuscular junction is con-
sidered a P/Q-type.23,24 Pathogenesis of paraneoplas-
tic LEMS is a three-step process.2
First, P/Q-type VGCC are suddenly expressed in the
SCLC. Second, anti-P/Q-type VGCC autoantibodies
are produced and the amount of P/Q-VGCC present
in the nerve endings as a result of immunological
cross-reactivity is reduced. Third, because of a
decrease in P/Q-type VGCC at nerve endings, the
influx of calcium ions is inhibited, resulting in
reduced release of acetylcholine and consequently
muscle strength is reduced. These results using neu-
ronal cells containing P/Q-type VGCCs provide direct
evidence that LEMS immunoglobulin G inhibits
neurotransmitter release by acting on P/Q-type
VGCC.25,26 However, an animal LEMS model by
immunizing purified P/Q-type VGCC has not been
successful, therefore, the identification of which
pathogenic autoantibodies are attacking P/Q type
VGCC is not yet conclusive.
P/Q-type VGCC is a channel protein, consisting of
a1, b, a2-d and c subunits, as shown in Figure 2.
The a1 subunit has a potential sensor function, hav-
ing a IV one domain from I, and each domain might
have a transmembrane portion from S1 to S6.
Regarding the main immunogenic region that
autoantibodies bind to causing reduction of the
amount of P/Q-type VGCC, the loop structure (red
circle, Fig. 2) connecting the S5 and S6 in IV from
domain I of the a1 subunit 7 is extracellular, and
these regions are speculated to be the main
immunogenic region.27–29
In LEMS patients, observing neuromuscular junc-
tions using an electron microscope shows there is no
complement-mediated membrane disruption at the
nerve endings,30–32 such as seen in acetylcholine
receptor antibody-positive MG as shown in
Figure 3.33 In addition, <10% of LEMS patients
develop cerebellar ataxia. P/Q-type VGCC autoanti-
bodies cross the blood–brain barrier, reducing the
amount of P/Q-type VGCC in the cerebellar molecu-
lar layer, which might cause paraneoplastic cerebellar
degeneration, as shown in Figure 4. In the cerebel-
lums of paraneoplastic cerebellar degeneration LEMS
patients, compared with control cerebellums, the
amount of P/Q-type VGCC in the cerebellar molecu-
lar layer decreased markedly, but the amount of N-
type VGCC and voltage-gated potassium channels in
the vicinity was normal.9 Pathogenic mechanisms
that show such conditions are not only considered to
Table 2 Classification and characteristics of voltage-gated calcium channels
Electrophysiological
Molecular










Brain, cardiac muscle, smooth muscle
Brain, Pancreas, auditory hair cell
Retina




N Cav2.2 9p34 M-conotoxin GVIA Brain, nerve







Ni2+, mibefradil, kurtoxin Brain, cardiac muscle
Brain
Brain
Figure 2 Schematic diagram of the P/Q-type voltage-gated calcium channel. Reproduced from Catterall23 with permission.
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be caused by autoantibodies. Thus, the authors specu-
late that the same mechanism for down-regulation of
P/Q-type VGCC in the cerebellar molecular layer is




Compound muscle action potential is remarkably
decreased in LEMS. This finding is specific to LEMS
and is not seen in MG. Repetitive stimulation fre-
quency is 2–50 Hz.34,35 Amplitude decrement is
recorded with 2–5 Hz low-frequency stimulation.
Amplitude is markedly increased at 50 Hz high-fre-
quency stimulation, which is termed the waxing
phenomenon.
P/Q-type VGCC antibody test
Specificity: P/Q-type VGCC autoantibodies are nega-
tive in almost all SCLC cases without LEMS.36
(a) (b) (c)
Figure 3 Electron micrograph of the neuromuscular junction of the biceps. In the (a) normal and (c) Lambert–Eaton myasthenic syndrome patients,
the postsynaptic structure is intact. (b) In myasthenia gravis patients, the expansion of the primary synaptic cleft and secondary synaptic cleft, and
degradation products of synaptic folds are observed. M, mitochondria; NT, nerve endings; SC, Schwann cell; SV, synaptic vesicles. *The primary synap-



























Figure 4 In the autopsied cerebellum of a Lambert–Eaton myasthenic syndrome (LEMS) with paraneoplastic cerebellar degeneration (PCD-LEMS)
patient, the amount of P/Q-type voltage-gated calcium channel of molecular layer is reduced. Autoradiographic localization of 125I-omega-conotoxin
MVIIC-binding sites in adjacent sections of autopsied cerebellar tissue. Hematoxylin–eosin staining in (a) a control patient and (d) a PCD-LEMS patient
(magnification: 964). Sections were exposed to 200 pM 125I-omega-conotoxin MVIIC either (b,e) without or (c,f) with 0.5 lmol/L unlabeled omega-con-
otoxin MVIIC. Compared with (b) the control patient, the toxin-binding sites of P/Q-type voltage-gated calcium channels of (e) the PCD-LEMS patient
were markedly reduced in the molecular layer. G, granular layer of the cerebellum; M, molecular layer of the cerebellum. Reproduced from Fukuda
et al.9 with permission.
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Seropositivity: they are positive in almost all LEMS
cases with SCLC, and in 85–90% of non-SCLC
LEMS patients.37–41
Saxon test
This test is useful to evaluate autonomic function in
LEMS patients. Sterilized gauze is chewed for 2 min,
and weighed. Normally, over 4 g of saliva is
secreted, but it is significantly decreased in LEMS
patients. Oral administration of 3,4-diaminopyridine
might increase saliva secretion.42
Diagnosis and differential diagnosis
Clinical symptoms and electrophysiological studies
are essential for diagnosis of LEMS. Of LEMS patients,
10–15% are P/Q-type VGCC antibody-negative.13,43
Patients with proximal muscle weaknesses, peripheral
neuropathy and symptoms resembling MG44 or
polymyopathy require differential diagnosis.45 More
than 60% of LEMS patients have coexisting SCLC.
Treatment
General principles of LEMS treatment focus on
detecting SCLC and its treatment. Treating SCLC
with chemotherapy, radiotherapy and/or surgery
could markedly improve LEMS symptoms.19 A LEMS
treatment manual was proposed by Professor New-
som-Davis46 of Oxford University and thereafter,
revised by Titulaer et al.3 (Fig. 4) and Evoli et al.47
Newsom-Davis’ research group has reported that
SCLC with LEMS have a better prognosis than those
without LEMS.20,21 This observation suggests that
immunological mechanisms of LEMS might delay
the progression of SCLC. More than 60% of LEMS
patients have concurrent malignancy (mostly SCLC),
and more than 80% present LEMS symptoms before
tumor detection. Thus, after the diagnosis of LEMS,
detection of malignancy must be carried out
immediately. Immunotherapy including steroid and
immunosuppressant therapies could facilitate tumor
progression in LEMS patients with SCLC. Palliative
treatment is recommended to treat LEMS with SCLC
with 3,4-diaminopyridine48–52 and/or cholinesterase
inhibitors to improve clinical symptoms, and focus
on treating the SCLC. It is recommended to proceed
with tumor detection before LEMS treatment; that
is, within 2 years of LEMS diagnosis.12
LEMS without malignancy is defined as those cases
without SCLC 2 years after LEMS diagnosis. Approxi-
mately 30% of LEMS patients are non-malignancy-
related in Japan. In these cases, initial treatment
includes 3,4-diaminopyridine and cholinesterase inhi-
bitors. If these treatments are ineffective, steroid
Figure 5 Treatment scheme for Lambert–Eaton myasthenic syndrome. Reproduced from Titulaer et al.3 with permission. SCLC, small cell lung cancer.
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therapy and immunosuppressants can be used. If the
immunotherapy does not sufficiently improve muscle
weaknesses and residual severe motor impairment
occurs, or in cases in which immunotherapy is con-
traindicated, plasma exchange53–55 and/or high-dose
intravenous immunoglobulin56–58 treatments are rec-
ommended. These treatments are selected with regard
to treatments used for MG. Rituximab is being consid-
ered for refractory LEMS patients and its utility has
been reported.59,60 Unfortunately, none of these
treatments above are covered by Japanese national
health insurance.
Conclusions
An important issue that remains in LEMS clinical
research is that animal models using active immu-
nization have not yet succeeded. Therefore, the
identities of pathogenic autoantibodies that attack
P/Q-type VGCC have not been conclusively shown.
In the clinical aspects, there is a limit to the clinical
application of calcium channel of antibody measure-
ment kits for insurance purposes, and the treatment
with 3,4-diaminopyridine requires further study.
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